



A patient's introduction to the **DecisionDx-UM Test**

Welcome

You have received this guide because your physician is considering ordering or has ordered the **DecisionDx-UM** gene expression profile test as part of your care. The **DecisionDx-UM** test is used routinely in the management of uveal melanoma in the U.S. and is recommended for use by the American Joint Committee on Cancer. Castle Biosciences Inc. has developed this guide in response to requests from physicians, nurses, and patients with the goal of promoting communication between you and your healthcare team regarding this test.¹

Who is Castle Biosciences?

Castle Biosciences is a company whose mission it is to serve individuals afflicted with rare cancers (fewer than 40,000 cases diagnosed per year) and those who care for them. Traditionally, the diagnosis and prognosis for cancer was based upon histopathology, which assesses the physical features of tumor cells under a microscope. Advances over the last two decades in molecular biology and genetics have confirmed that a tumor's aggressiveness (prognosis) and response to therapy are best understood if the molecular biology (sometimes referred to as the molecular profile or signature or footprint) is evaluated in conjunction with the tumor's histopathology. This combination approach has been developed and applied to common cancers, such as breast cancer, colon cancer, and lung cancer. Unfortunately, this approach has not been well developed in rare cancers. Here at Castle Biosciences, we believe that rare cancers deserve the same focus. As a result, we are working with leading cancer treatment centers to identify and develop molecular diagnostic tests that assist the physician in achieving better outcomes for their patients.

Information

We are pleased that you and your doctor have chosen to consider the **DecisionDx-UM** gene expression profile test as part of your clinical care. This laboratory test provides you and your physician with important information regarding the molecular signature (also known as the gene expression profile) of your uveal melanoma tumor and how likely it is to metastasize (spread) in the near future.

Collaboration

You and your doctor are in the process of gathering as much information as possible to determine the best way to proceed in your unique situation (called a comprehensive baseline evaluation). The **DecisionDx-UM** test is one such piece of information. This test result will give your doctor an accurate prediction of your tumor's likelihood of metastasis (spreading) in the near term (3-5 years). **DecisionDx-UM** measures the molecular signature of your tumor and places it into one of two groups:

- Class 1.** Class 1 uveal melanoma tumors have a low risk of spreading in the near term; or
- Class 2.** Class 2 uveal melanoma tumors have a relatively high risk of spreading.

Decision Making

While the **DecisionDx-UM** test cannot, at this point, guide your doctor toward specific therapies based on your results, it can provide a framework for discussion between you and your doctor regarding how best to proceed. If you have a Class 1 tumor, this is valuable information to have as routine monitoring is likely a reasonable option, saving more aggressive treatment options for later should they become necessary. Conversely, if your test results identify your tumor as Class 2, perhaps a more aggressive approach to monitoring and initial treatment should be considered which might include clinical trial participation, etc...

Frequently Asked Questions

Will the DecisionDx-UM test help me?

What this test does is provide information about how likely your tumor is to metastasize (spread) in the near term (within 3-5 years). It is the only commercially available predictor of this information available to date.

How can I order this test?

Your physician is the only one who can order the test. If you wish to have it done, you should discuss it with your doctor.

What kind of specimen does the test require?

The majority of patients with uveal melanoma are treated with eye-sparing treatments such as plaque radiation therapy and proton-beam radiation therapy. Therefore, the **DecisionDx-UM** test is most commonly run on tumor tissue obtained from a procedure called Fine Needle Aspirate Biopsy (FNAB). Your physician will give you specific information regarding FNAB and any associated risks/benefits. As the effects of radiation may change the gene expression profile of your tumor tissue, it is important that you decide if you want to have this test prior to the treatment of your tumor so that the tumor tissue can be obtained prior to your uveal melanoma eye treatment.

Some patients have a uveal melanoma that is not able to be treated with eye-sparing treatments. These patients will likely undergo an enucleation procedure (removal of the eye). The **DecisionDx-UM** test can also be run on tumor tissue that is obtained following enucleation. In this case preserved sections or slides of the tumor would be obtained from the pathology laboratory.

What do test results look like?

Results will be sent to your doctor in a report that:

- (1) classifies your tumor as either Class 1 or Class 2,
- (2) describes the statistics associated with that class, and
- (3) provides the discriminant value for the classification (similar to a level of confidence regarding the classification)

Is the DecisionDx-UM test the same as the monosomy 3 (chromosome 3) test?

No. The **DecisionDx-UM** test measures the expression levels of 15 genes. The monosomy 3 looks to see if one of the chromosome 3 arms has been deleted or lost (so called monosomy 3). The **DecisionDx-UM** test has been directly compared to the monosomy 3 test and was proven to outperform the chromosome 3 test in predicting metastatic risk.

Does Castle have a Financial Assistance Program?

Castle sponsors an industry-leading financial assistance program that is broadly need-based. You can get more information regarding these programs by calling our customer service department and selecting option #3.

Where can I get more information on the DecisionDx-UM test?

Additional information can be found on the Castle Biosciences website. www.CastleBiosciences.com

Customer Service

1.866.788.9007 • www.CastleBiosciences.com

Provided as a service by



Footnotes

¹As of Mar, 2011, the DecisionDx-UM test is routinely ordered in over 55 of the estimated 70 ocular oncology services. Version 7 of the American Joint Committee on Cancer (AJCC) cancer staging manual was released in 2010. The AJCC guidelines are the only national guidelines that review uveal melanoma. The guidelines recommend the use of the DecisionDx-UM test (aka gene expression profile) as the results are defined to be 'clinically significant'.

DecisionDx-UM is a trademark of Castle Biosciences Inc.

©Castle Biosciences Inc, 2011. Version 3.0.